G&S Capital LLC Increases Position in Pfizer Inc. (NYSE:PFE)

G&S Capital LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 36.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 100,163 shares of the biopharmaceutical company’s stock after buying an additional 26,891 shares during the period. Pfizer comprises 1.2% of G&S Capital LLC’s portfolio, making the stock its 21st largest holding. G&S Capital LLC’s holdings in Pfizer were worth $2,780,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GoalVest Advisory LLC raised its holdings in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth $32,000. VisionPoint Advisory Group LLC raised its stake in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer in the 4th quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in Pfizer in the 4th quarter valued at about $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $35.86.

Pfizer Stock Performance

Shares of PFE stock opened at $27.42 on Thursday. The firm has a market capitalization of $155.38 billion, a price-to-earnings ratio of -456.92, a price-to-earnings-growth ratio of 1.10 and a beta of 0.70. The company has a 50 day moving average price of $27.77 and a 200 day moving average price of $27.69. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the prior year, the firm posted $1.23 EPS. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.13%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.